Pacira Biosciences, Inc. · NASDAQ:PCRX
Pacira Biosciences — Q3 2025 Earnings Presentation
21 slides from Pacira Biosciences's earnings presentation, Nov 6, 2025
Slide 1: 3Q25 Earnings Presentation
3Q25 Earnings Presentation PCRX | November 2025
Slide 2: Forward-looking statements and where to find additional information
Forward-looking statements and where to find additional information Any statements in this presentation about Pacira’s future expectations, plans, trends, outlook, projections and prospects, and other statements containing the words “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “int
Slide 3: Accelerating growth in base business, advancing pipeline value
ACCELERATING GROWTH IN BASE BUSINESS ADVANCING PIPELINE VALUE 1 2 3 4 5 More than 3 million Double-digit 5-percentage Clinical pipeline Establishing patients treated compounded point gross margin expansion with 5 partnerships per year annual growth rate improvement over 5 novel programs including pi
Slide 4: Accelerating growth in base business: patients treated
ACCELERATING GROWTH IN BASE BUSINESS >3M ~2.6M 2.4M 2.2M 2.3M Patients: More than 3 million patients treated per year 2022 2023 2024 2025 2026 2027 2028 2029 2030 Better is possible. 4
Slide 5: Accelerating growth in base business: product revenue
ACCELERATING GROWTH 2025 YoY EXPAREL volume growth IN BASE BUSINESS >$1.1B Highest volume 9% $725M- growth in $735M 6% >3 years 3% $675M $701M 1Q 2Q 3Q Product revenue: Double-digit ~2.6% CAGR >10% CAGR compounded annual growth rate 2023 2024 2025 2030 Better is possible. 5
Slide 6: Profitability: favorable gross margins support 2nd increase in guidance
Favorable gross margins support 2nd increase in guidance ACCELERATING GROWTH IN BASE BUSINESS 85% ≥ 81% 80-82% 82% 80-82% 80% 78-80% 76-78% 78% 75% 3Q24 3Q25 Feb ‘25 Aug ‘25 Nov ‘25 Profitability: 5-percentage point 76% gross margin improvement over 2024 2025 2030 2024 Better is possible. 6
Slide 7: Advancing pipeline value
ADVANCING PIPELINE VALUE Clinical development stage Next clinical Product candidate Target Preclinical P1 P2 P3 milestone 1 Phase 2 Part B PCRX-201 Knee OA enrollment begins (Mid 2026) Pipeline: 2 AMT-143 Postsurgical pain Phase 2 program launch (2026) Clinical pipeline expansion with 5 novel progra
Slide 8: Partnerships
ADVANCING PIPELINE VALUE 1 Partnerships: Partner Establishing 5 partnerships including pipeline Product and commercial agreements Region U.S. Year 2025 Better is possible. 8
Slide 9: Improving trends within commercial portfolio
Improving trends within commercial portfolio Rising momentum from strong Significantly expanding reach resulting from execution expanding through with dedicated sales force and other and J&J MedTech commercial investments GPO’s and performance-based J&J team trained Growing uplift from medial contra
Slide 10: Becoming the therapeutic area leader in musculoskeletal pain and adjacencies
Becoming the therapeutic area leader in musculoskeletal pain and adjacencies Advancing an innovative pipeline PCRX-201 (enekinragene inzadenovec) Clinical Preclinical In-licensing of AMT-143, a novel, long-acting Prioritizing three HCAd-based programs in Part A of P2 ASCEND study – formulation of Ro
Slide 11: Key data catalysts expected to begin in 2026
Key data catalysts expected to begin in 2026 Product Target 2025 2026 2027+ Innovative Pipeline Phase 2 ASCEND Clinical Trial: Part A 2026: Phase 2 Part A topline PCRX-201 Knee OA Phase 2 ASCEND Clinical Trial: Part B Commercial Base Pediatric 0 to <6 PK/Safety Clinical Trial Shoulder OA Registratio
Slide 12: EXPAREL franchise well protected from multiple directions
EXPAREL franchise well protected from multiple directions A great deal has changed since the first generic filer Claiming composition of EXPAREL produced by our enhanced large-scale manufacturing processes in Swindon, UK and San Diego, CA 14 Erucic acid family 4 IVRA family • Result of EXPAREL made
Slide 13: Strong progress across three key commercial priorities
Strong progress across three key commercial priorities Better is possible. 13
Slide 14: >100M Market Access
>100M total covered lives expected across both commercial and government payers by year end ~90M 1Q 2Q 3Q total covered lives across both commercial and government payers as of 3Q25 Market Top 5 states TX 3Q YoY volume Access account for FL growth of CA NJ collectively in these markets NC 15% of EXP
Slide 15: Awareness
Website traffic up Awareness 6 Rolled out several targeted digital pilot across both consumer programs in 1H25 to advance patient and and healthcare physician awareness provider platforms and engagement since launch Better is possible. 15
Slide 16: Utilization
YoY Volume Growth 30% More streamlined decision-making in 25% ASCs and community ASCs hospitals, enabling faster adoption 20% Utilization 15% 10% Improving growth in Hospital setting despite challenging elective 5% surgery market 0% 2Q25 3Q25 ASC Community Hospital Hospital Better is possible. Abbre
Slide 17: Significant cashflow generation to advance strategy and create shareholder value
Significant cashflow generation to advance strategy and create shareholder value $ in M $ in M 3Q25 2025 Financial Guidance Updated as of 3Q25 EXPAREL $140 Total Revenue $725-735 ZILRETTA $29 Non-GAAP Gross Margins 80-82% iovera° $6 Total Revenue $180 Non-GAAP R&D $95-105 Non-GAAP Gross Margins 82%
Slide 18: Disciplined capital allocation strategy to drive shareholder value
Disciplined capital allocation strategy to drive shareholder value • Established commercial, medical & market access powerhouse Accelerating • Life cycle management programs in areas of high unmet need with favorable return on 1 growth in base invested capital business • Educating patients and provi
Slide 19: Website, Investor toolkit, Social
Website Investor-toolkit Social: X Social: LinkedIn
Slide 20: Appendix
APPENDIX Better is possible. 20
Slide 21: Non-GAAP disclosure
Non-GAAP disclosure Pacira BioSciences, Inc. Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA (Non-GAAP) (in thousands) (unaudited) 3Q25 GAAP net income (loss) $ 5,432 Interest income (8,534) Interest expense (1) 4,279 Income tax expense 4,092 Depreciation expense 6,869 Amortization of ac